Correlation of endogenous acetyl-ser-asp-lys-pro plasma levels in mice and the kinetics of pluripotent hemopoietic stem cells entry into the cycle after cytosine arabinoside treatment: fundamental and clinical aspects
- PMID: 1602798
Correlation of endogenous acetyl-ser-asp-lys-pro plasma levels in mice and the kinetics of pluripotent hemopoietic stem cells entry into the cycle after cytosine arabinoside treatment: fundamental and clinical aspects
Abstract
A decrease of endogenous acetyl-ser-asp-lys-pro (AcSDKP) levels in murine plasma was observed after Ara-C treatment. This decrease preceded the entry of pluripotent hemopoietic stem cells (CFU-S) into the cell cycle. This suggests a correlation between CFU-S kinetics and levels of endogenous AcSDKP. The subsequent increase of AcSDKP levels seem to indicate a feedback mechanism which should permit the reestablishment of homeostasis in the stem cells. Therefore, the expulsion of the physiological brake may be the response to a signal (stimulatory factors) to start dividing and the retention of the physiological brake may the mechanism for a return to normal values of cell proliferation.
Similar articles
-
Human placental low molecular weight factors inhibit the entry into cell cycle of murine pluripotent stem cells.Leukemia. 1991 Mar;5(3):270-2. Leukemia. 1991. PMID: 2013983
-
Activated granulocytes oxidize the endogenous stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) to the stimulatory dimer: a redox-mediated mechanism for demand-induced hematopoietic regulation.Exp Hematol. 1998 Aug;26(9):851-8. Exp Hematol. 1998. PMID: 9694506
-
The physiological role of the endogenous colony forming units-spleen (CFU-S) inhibitor acetyl-N-Ser-Asp-Lys-Pro (AcSDKP).Leukemia. 1989 Oct;3(10):753-4. Leukemia. 1989. PMID: 2779291
-
Inhibitory peptides in hematopoiesis.Exp Hematol. 1995 Jun;23(6):477-81. Exp Hematol. 1995. PMID: 7768302 Review.
-
The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.Cancer Treat Rev. 1990 Sep;17(2-3):347-54. doi: 10.1016/0305-7372(90)90068-q. Cancer Treat Rev. 1990. PMID: 2272050 Review.
Cited by
-
Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia.Exp Ther Med. 2018 Jun;15(6):5431-5435. doi: 10.3892/etm.2018.6111. Epub 2018 Apr 30. Exp Ther Med. 2018. PMID: 29904422 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical